Will the FDA approve any psychedelic substance for medical use this year?
5.0 pts (24h)Health & MedicineOne-Off3m
KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosRazoavelmente calibradoProbabilidade implícita atual
Não 68%
Qualidade do mercado
64 / 100
Qualidade médiaVolume 24h
49,5 €
Liquidez
77,1 mil €
Alta liquidezCompra / Venda
29.0% / 33.0%
Spread
4.0 pt
Spread moderadoDados do mercado
Atualizado há 12 minutos
17/07/25, 14:00 UTC1/01/27, 04:59 UTC
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
Will the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve MDMA for PTSD?
KalshiWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWill a psychedelic substance get de-scheduled by the US by 2030?
Manifold MarketsRegras
If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
- Important information: For purposes of this Contract:
- The listed substances are illustrative, not exhaustive.
- Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
- "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.
Mercados abertos
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Volume total
- € 15,6 mi
- Volume 24h
- € 18 mil
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Volume total
- € 920,1 mil
- Volume 24h
- € 4 mil
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 mais resultados
- Volume total
- € 2,6 mil
- Volume 24h
- € 2,6 mil
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt98%
- Above 6000+2.0pt61%
+2 mais resultados
- Volume total
- € 868,1 mil
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 mais resultados
- Volume total
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Volume total
- € 612,7 mil
- Volume 24h
- € 1,2 mil
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- What will RFK say during RNC Midterm Convention?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Measles cases in U.S. by September 30?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
Perguntas frequentes
- Quais são as probabilidades atuais de Will the FDA approve any psychedelic substance for medical use this year??
- A Kalshi cota No em 68% em 10 de setembro de 2026.
- Quando Will the FDA approve any psychedelic substance for medical use this year? é resolvido?
- Will the FDA approve any psychedelic substance for medical use this year? deverá ser resolvido em 1 de janeiro de 2027.
- Como Will the FDA approve any psychedelic substance for medical use this year? é liquidado?
- A Kalshi liquida este mercado da seguinte forma: If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.